Breaking Down Xvivo Perfusion AB (publ) Financial Health: Key Insights for Investors

XVIVO Perfusion AB's recent numbers demand attention: in Q2 2025 the company reported net sales of SEK 178 million, a 15% decline year‑over‑year with organic sales down 11%, while the abdominal segment grew organically 19% to SEK 52 million as the thoracic segment fell 19% to SEK 105 million; Q1 2025 net sales were SEK 219 million (+16% YoY) and full‑year 2024 revenue reached SEK 822.4 million (+37.63% vs 2023). Profitability signals are mixed: Q2 2025 adjusted EBITDA margin dropped to 13% from 24% a year earlier, gross profit was SEK 133 million with a stable 74% gross margin, and TTM EPS stands at 0.07 with TTM net income of SEK 2.36 million. Balance‑sheet and market metrics show cash of SEK 323 million as of June 30, 2025 (down from SEK 481 million), a market capitalization of SEK 413.3 million (‑60.65% year‑over‑year) and enterprise value SEK 400.82 million, while valuation multiples include a TTM P/S of 6.29 and a TTM P/E of 175.07. Liquidity and operations reflect pressure-Q2 cash flow from operations was SEK 9 million versus SEK 25 million a year earlier and the stock fell 23% after the Q2 release-yet growth initiatives and milestones remain on the roadmap: nine patients enrolled in the US Continuous Access Protocol as of end‑Q3 2025, a planned FDA heart filing by Q2 2026, a 70% gross‑margin target for the abdominal segment by 2027, and roughly 200 employees supporting expansion in North America and Europe.

Xvivo Perfusion AB (0RKL.L) - Revenue Analysis

Q2 2025 marked a pullback in sales for Xvivo Perfusion AB (0RKL.L), with notable divergence between thoracic and abdominal product lines and relatively stable services. Key figures and trends are summarized below.

• Net sales Q2 2025: SEK 178 million (down 15% vs. SEK 210 million in Q2 2024).
• Organic growth Q2 2025: -11% year-over-year.
• Net sales Q1 2025: SEK 219 million (reported as 16% total growth vs. Q1 2024).
• Annual revenue 2024: SEK 822.4 million, a 37.63% increase from SEK 597.5 million in 2023.

• Segment dynamics: abdominal segment is the primary growth driver in Q2 2025 (+19% organic), while thoracic contraction (-19% organic) is the main contributor to the overall revenue decline.
• Services remain relatively stable but slightly down year-over-year (SEK 21m vs. SEK 23m), indicating consistent, low-volatility recurring revenue.
• Quarter-to-quarter: Q1 2025's SEK 219m (reported +16% YoY) versus Q2 2025's SEK 178m signals short-term seasonality or demand variability that investors should monitor across subsequent quarters.
• Annual context: significant scaling in 2024 (SEK 822.4m, +37.63% YoY) establishes a higher revenue base; comparisons to 2025 should account for that enlarged base.

Further investor-focused context and shareholder composition can be reviewed here: Exploring Xvivo Perfusion AB (publ) Investor Profile: Who's Buying and Why?

Xvivo Perfusion AB (0RKL.L) - Profitability Metrics

Key profitability indicators for Xvivo Perfusion AB (0RKL.L) highlight recent margin pressure in 2025 vs. prior improvements in 2024 and the company's current market valuation relative to sales and earnings.

• Q2 2025 adjusted EBITDA margin: 13% (down from 24% in Q2 2024).
• Q4 2024 adjusted EBITDA margin: 23% (demonstrating improved operational efficiency at that time).
• Q2 2025 gross profit: SEK 133 million (Q2 2024: SEK 158 million); gross margin: 74% (stable year-over-year).
• TTM net income (as of 12 Dec 2025): SEK 2.36 million.
• TTM price-to-sales (P/S): 6.29.
• TTM earnings per share (EPS): 0.07 SEK.

For context on company purpose and strategic orientation, see Mission Statement, Vision, & Core Values (2026) of Xvivo Perfusion AB (publ).

Xvivo Perfusion AB (0RKL.L) - Debt vs. Equity Structure

• Balance posture: EV slightly below market cap reflects a capital structure where cash is large relative to debt; implied gross debt ~SEK 310.5m produces a small net cash position (~SEK 12.5m).
• Liquidity trend: cash declined SEK 158m year-over-year (SEK 481m → SEK 323m) which tightens short-term liquidity available for operations or R&D.
• Valuation signal: TTM P/E of 175.07 indicates investors are pricing significant future growth or a low current earnings base; market cap decline (~60.65% YoY) shows market repricing risk.
• Operational scale vs. capital needs: ~200 employees support ongoing commercialization and product development but maintain fixed cost base while cash declined.

• Equity story emphasis: management positions Xvivo Perfusion AB on long-term value creation via innovative preservation and perfusion technologies; strategic messaging centers on durable clinical benefits and market expansion.
• Investor considerations: monitor cash-burn trajectory, any refinancing or debt repayment activity tied to the implied SEK 310.5m gross debt, and progress on commercial milestones that justify the high P/E.

Xvivo Perfusion AB (0RKL.L) - Liquidity and Solvency

Key liquidity and solvency metrics for Xvivo Perfusion AB (0RKL.L) indicate tightening operating cash generation and a reduced cash buffer against obligations, while valuation multiples remain elevated.

• Operating cash flow (Q2 2025): SEK 9 million (Q2 2024: SEK 25 million)
• Cash position (June 30, 2025): SEK 323 million (June 30, 2024: SEK 481 million)
• Market capitalization (Nov 17, 2025): SEK 413.3 million (down 60.65% year-on-year)
• Enterprise value: SEK 400.82 million
• TTM P/E ratio: 175.07

Implications for stakeholders:

• Reduced operating cash generation (Q2 2025 vs Q2 2024) may increase reliance on existing cash or external financing if trends persist.
• Cash balance decline (SEK 323M vs SEK 481M) narrows the runway for investment and working capital needs.
• Enterprise value slightly below market cap suggests limited net debt or small cash adjustment; assess balance sheet detail for net cash/debt position.
• Very high TTM P/E (175.07) signals market expectations for future earnings growth; risk of valuation compression if growth disappoints.
• Equity story continues to emphasize long-term value creation through innovative preservation and perfusion technologies, which underpins investor sentiment despite near-term liquidity pressures.

Further reading: Exploring Xvivo Perfusion AB (publ) Investor Profile: Who's Buying and Why?

Xvivo Perfusion AB (0RKL.L) - Valuation Analysis

• TTM Price-to-Sales (P/S): 6.29 - investors are paying SEK 6.29 for each SEK 1 of trailing sales, implying growth/quality expectations priced into the stock.
• TTM Earnings Per Share (EPS): 0.07 SEK - trailing EPS is positive but small, constraining profit-based valuation measures.
• TTM Price-to-Earnings (P/E): 175.07 - an elevated P/E reflecting high valuation relative to scant earnings; sensitive to small EPS fluctuations.
• Market Capitalization (as of 2025-11-17): SEK 413.3 million - a 60.65% decline year-over-year, signaling material market de-rating or earnings/operational stress.
• Enterprise Value (EV): SEK 400.82 million - close to market cap, indicating limited net debt or small differences between equity and total enterprise valuation.
• Equity story: focused on long-term value creation via innovative organ preservation and perfusion technology; valuation reflects expected future growth and commercialization potential.

• Valuation drivers: anticipated revenue growth from product adoption, margin expansion from scale, and continued R&D/clinical progress.
• Valuation risks: earnings sensitivity, execution risk on commercialization, potential capital raises diluting equity, and market sentiment given the 60.65% market-cap decline.
• Investor implications: P/S of 6.29 versus P/E of 175.07 suggests investors are paying for sales and future growth rather than current earnings - requires conviction in the equity story and monitoring of margin and revenue trajectories.

Xvivo Perfusion AB (0RKL.L) - Risk Factors

• US market headwinds: public healthcare funding cuts and a decline in waiting-list volumes are reducing procedure throughput and purchaser budgets for EVLP systems and consumables.
• Adoption slowdown: EVLP technology uptake has decelerated versus prior forecasts, constraining unit sales and recurring revenue from disposables.
• Share-price volatility: the stock dropped 23% after the Q2 2025 earnings release, reflecting investor concern about guidance and execution.
• High valuation vs. earnings: trailing twelve months (TTM) P/E of 175.07 signals a steep premium relative to current earnings, increasing sensitivity to any earnings misses.
• Premium relative to sales: TTM price-to-sales (P/S) of 6.29 implies elevated market expectations for future top-line growth that may be hard to meet if adoption slows.
• Capitalization erosion: market cap was SEK 413.3 million as of November 17, 2025, down 60.65% year-over-year, reducing balance-sheet market confidence and potentially limiting access to equity financing.

Xvivo Perfusion AB (0RKL.L) - Growth Opportunities

The following chapter highlights the near-term and medium-term growth opportunities for Xvivo Perfusion AB (0RKL.L) based on the company's recent operating metrics and strategic roadmap.

• Q2 2025 abdominal segment performance: organic growth of 19% with net sales of SEK 52 million (Q2 2024: SEK 47 million).
• Geographic expansion priorities: increased penetration in North America and Europe - launching heart technology in Europe and scaling EVLP (ex vivo lung perfusion) in North America.
• Margin target: aiming for a 70% gross margin in the abdominal segment by 2027.
• Service-led growth in the US: strengthening the US service business via strategic partnerships and targeted investments to underpin future heart business expansion.
• Clinical and regulatory milestones: nine patients enrolled in the US Continuous Access Protocol as of end-Q3 2025; planned FDA heart regulatory submission by Q2 2026.

Key strategic initiatives and levers to realize growth:

• Commercial roll-out: staged launch of heart technology in Europe followed by regulatory-driven expansion in North America.
• EVLP scale-up in North America: increase utilization and billing events through hospital partnerships and reimbursement engagement.
• Service platform build: expand US service footprint, reinforce training, and establish maintenance/service contracts to create recurring revenue.
• Margin improvement programs: procurement optimization, manufacturing scale, and product mix shift to reach the 70% abdominal gross margin objective by 2027.
• Clinical/regulatory execution: maintain enrollment momentum in the US Continuous Access Protocol and meet the Q2 2026 FDA submission timeline.

Financial and operational indicators investors should monitor going forward:

• Quarterly abdominal segment sales and organic growth rates versus the 19% Q2 2025 baseline.
• Gross margin trajectory for the abdominal segment toward the 70% 2027 target.
• Progress in US service partnerships and contribution of service revenue to recurring revenue mix.
• Clinical enrollment updates and timing of regulatory submissions/approvals (notably the planned Q2 2026 FDA filing).
• Geographic revenue split (Europe vs North America) as heart product commercialization begins in Europe and EVLP expands in North America.

For context on corporate purpose and long-term orientation, see Mission Statement, Vision, & Core Values (2026) of Xvivo Perfusion AB (publ).